SEE THE OPZELURA DIFFERENCE

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

Significant skin clearance within weeks1,2

Significant skin
clearance within weeks1,2

Patient 1’s knee with visible red patches indicating inflammation and lesions associated with AD.Patient 1’s knee with visible red patches indicating inflammation and lesions associated with AD.

Click to see the difference +

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

Significant skin clearance within weeks1,2

Significant skin
clearance within weeks1,2

Patient 2’s skin before treatment with OPZELURA; red patches indicate inflammation and lesions associated with ADPatient 2’s skin before treatment with OPZELURA; red patches indicate inflammation and lesions associated with AD

Click to see the difference +

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

View itch data >

EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; IGA-TS=Investigator's Global Assessment Treatment Success.

References: 1. Data on file. Incyte Corporation. 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2021.